Agenus | AGEN - Loan Capital


Agenus reported $153.98M in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
AbbVie USD 64.53B 5.59B Mar/2026
Agenus USD 153.98M 15.68M Mar/2026
Amgen USD 51.86B 27M Jun/2026
AstraZeneca USD 26.01B 46M Jun/2026
Bristol-Myers Squibb USD 42.09B 59M Jun/2026
CSL USD 10.42B 273M Dec/2025
Eli Lilly USD 39.37B 1.5B Mar/2026
Gilead Sciences USD 20.86B 1.27B Mar/2026
GlaxoSmithKline GBP 13.95B 65M Jun/2026
Glaxosmithkline GBP 18.53B 1.29B Mar/2026
Incyte USD 28.42M 994K Jun/2026
Intrexon USD 0 198.67M Jun/2024
J&J USD 37.34B 183M Jun/2026
Jiangsu Hengrui CNY 37.1M 6.2M Mar/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
MacroGenics USD 68.71M 1.29M Mar/2026
Merck EUR 10.8B 72M Mar/2026
Merck USD 46.67B 77M Mar/2026
Northwest Biotherapeutics USD 16.21M 15.59M Mar/2026
Novartis USD 37.49B 42M Jun/2026
Novavax USD 246.3M 200K Dec/2025
Pfizer USD 60.5B 70M Jun/2026
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Rigel Pharmaceuticals USD 0 0 Sep/2024
Sangamo BioSciences USD 0 0 Jun/2022
Veracyte USD 0 0 Mar/2025